These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 29602266

  • 1. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 2. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
    Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, Chandrasekar P, Haririan A.
    Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J, Heredia-Pimentel A, Rojas-Campos E, Ramírez Flores D, Cerrillos-Gutierrez JI, Miranda-Díaz AG, Evangelista-Carrillo LA, Martínez-Martínez P, Jalomo-Martínez B, Gonzalez-Espinoza E, Gómez-Navarro B, Medina-Pérez M, Nieves-Hernández JJ.
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [Abstract] [Full Text] [Related]

  • 4. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 6. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 7. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V, Sintes H, López-Gallo C, Delgado M, Santos F, Zurbano F, Solé A, Gavaldá J, Borro JM, Redel-Montero J, Cifrian JM, Pastor A, Román A, Ussetti P.
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [Abstract] [Full Text] [Related]

  • 8. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C, Preiksaitis JK, Cervera C, University of Alberta Cardiothoracic Transplant GroupDivision of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada..
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [Abstract] [Full Text] [Related]

  • 9. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [Abstract] [Full Text] [Related]

  • 10. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 11. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 15; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

  • 12. High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.
    Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser P, Ring WS, DiMaio JM, Drazner MH.
    J Heart Lung Transplant; 2008 May 15; 27(5):536-9. PubMed ID: 18442720
    [Abstract] [Full Text] [Related]

  • 13. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 15; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 15; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 15. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 15; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 16. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
    Eriksson M, Jokinen JJ, Söderlund S, Hämmäinen P, Lommi J, Lemström K.
    Transpl Infect Dis; 2018 Jun 15; 20(3):e12868. PubMed ID: 29512249
    [Abstract] [Full Text] [Related]

  • 17. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, Mieno M, Shirakawa H.
    Int J Infect Dis; 2017 Dec 15; 65():50-56. PubMed ID: 28986314
    [Abstract] [Full Text] [Related]

  • 18. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 15; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 15; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 20. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec 15; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.